Published on 29/11/2025

Storyboards for ATMP PPQ/CPV in Inspections

In the ever-evolving landscape of advanced therapy medicinal products (ATMP), ensuring compliance with regulatory expectations is paramount. This article serves as a detailed tutorial on the development and implementation of storyboards tailored for the Process Performance Qualification (PPQ) and Continued Process Verification (CPV) of ATMPs during regulatory inspections. We will discuss critical elements such as viral clearance validation, spiking studies, closed and single-use systems, and aseptic controls outlined in Annex 1.

Understanding the Regulatory Landscape for ATMPs

The regulatory frameworks set by organizations such as the FDA, EMA, and MHRA provide guidance on the evaluation and approval of ATMPs. These guidelines are crucial for ensuring that ATMPs are manufactured and controlled to the highest standards. The ICH Q5A(R2) guideline specifically addresses the need for viral safety, which is a critical factor in the lifecycle of biological products.

Understanding these regulations ensures that manufacturers can effectively plan and implement strategies for successful ATMP development. Companies must align their procedures with these guidelines to facilitate the approval process and ensure patient safety. The requirements outlined in the guidelines encompass the entirety of product lifecycle from implanting quality by design (QbD) principles to ensuring product consistency.

Developing Effective Storyboards for ATMP PPQ and CPV

Storyboards serve as visual representations of processes and workflows, making them instrumental in communication among stakeholders involved in the ATMP development process. When preparing storyboards for PPQ and CPV, validating certain elements of the production and testing procedures is crucial.

Step 1: Identify Key Quality Attributes (CQAs)

The first step in developing a storyboard is the identification of key quality attributes (CQAs), specifically potency and identity CQAs. It is essential to determine which characteristics of the ATMP are critical to its quality and efficacy. This process involves cross-functional collaboration between scientists, quality assurance, and regulatory affairs professionals.

• Gather the team and review relevant product documentation.
• Identify attributes that directly impact product quality, safety, and efficacy.
• Classify CQAs into categories such as potency and identity.

Step 2: Define the Process Flow

Once CQAs are identified, the next task is to define the process flow related to the production of the ATMP. This involves mapping out each step in the manufacturing process, including:

• Cell line development
• Culture expansion
• Purification
• Formulation
• Filling and finishing

For each stage of production, incorporate controls and assessments related to the identified CQAs. Ensure that all relevant checks are documented in the storyboard to delineate responsibilities and timelines.

Step 3: Incorporate Viral Clearance Validation

Viral clearance validation is a cornerstone of ATMP quality assurance. When tailoring the storyboard for PPQ, ensure that spiking studies and viral clearance tests are adequately planned and depicted within the process map.

• Design spiking studies that simulate viral contamination during important production steps.
• Determine appropriate viral validation methods according to ICH guidelines.
• Document outcomes and utilize the results to improve process control.

Step 4: Detailed Mapping of Chains of Identity and Custody

The chain of identity (COI) and chain of custody (COC) are essential elements in the development of ATMPs. It is critical to ensure traceability of materials and products throughout the manufacturing process. The storyboard must visually represent how each component is tracked, monitored, and verified.

• Map out the entire workflow from raw materials to final product delivery.
• Incorporate tracking systems that provide real-time information on the status of materials.
• Establish protocols for documentation and verification at each step in the process.

Step 5: Integrate Closed and Single-Use Systems

The use of closed systems and single-use technologies is increasingly prevalent in the manufacture of ATMPs. These systems help mitigate contamination risks while enhancing operational efficiency. The storyboard should include details on how these systems will be integrated into the production process.

• Detail the types of closed systems employed in the manufacturing steps.
• Indicate how single-use components minimize cross-contamination risks.
• Outline any specialized training or SOPs required for personnel working with these systems.

Validation of Aseptic Processing Controls as per Annex 1

Aseptic controls are highlighted in Annex 1 of the European Medicines Agency guidelines, serving as a pivotal standard for ATMP manufacturing. When developing storyboards, it is essential to underscore procedures that maintain sterility throughout the production process.

Characterizing Aseptic Controls

Key elements of aseptic controls that should be captured in the storyboard include:

• Environmental monitoring procedures
• Personnel hygiene protocols
• Use of sterilized equipment and materials

Implementing and validating these aseptic process controls helps safeguard against potential contamination, which is vital for maintaining product integrity.

Process Simulation and Control Strategy

Implementing a control strategy for aseptic processing involves simulating the aseptic environment and conducting testing to validate that procedures are effective. Validate the storyboard by incorporating these strategies:

• Establishing a simulation environment for aseptic operations.
• Detailing the use of bioburden testing and end-product sterility tests.
• Defining specific acceptance criteria that must be met.

Preparing for Regulatory Inspections

Once the storyboard is developed and validated, the next step is ensuring readiness for potential regulatory inspections involving FDA, EMA, or MHRA. The storyboard provides a framework for discussion with regulators and demonstration of compliance.

Conduct Mock Inspections

Before the actual inspection occurs, conducting mock inspections can be valuable for assessing the robustness of your processes and the effectiveness of your storyboards. This aspect includes:

• Engaging cross-functional teams to simulate an inspection scenario.
• Reviewing the storyboard to ensure all critical aspects are ready for evaluation.
• Identifying gaps in the processes and addressing weaknesses.

Documentation and Training

Ensure that all relevant documentation supporting the storyboard is easily accessible. Training staff on the storyboard and its importance enhances preparedness:

• Organize training sessions about the storyboard’s content.
• Prepare staff for questions that may arise during inspections.
• Continuously update training material to reflect changes in process or regulation.

Final Considerations

The development and implementation of effective storyboards for ATMP PPQ and CPV represent a critical component of regulatory compliance and quality assurance. By integrating the above steps, pharmaceutical professionals can ensure that their products not only meet regulatory expectations but also maintain the safety and efficacy required for patient care.

Ultimately, a thorough and comprehensive storyboard can act as a vital communication tool with regulatory bodies, demonstrating the organization’s commitment to quality in ATMP manufacturing.